Clinical trial

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)

NCT05171816

Study summary

ClinicalTrials.gov

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)

Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE3

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record olaparib Normalized identity: olaparib View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record abiraterone acetate Normalized identity: abiraterone acetate View linked drug · Find medicine records · Find other trials using this name

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2021-06-24

PhasePHASE3

Conditions

Metastatic Castration-resistant Prostate Cancerunresolved

Interventions

olaparibDRUG · verified · RxNorm: olaparib

abiraterone acetateDRUG · verified · RxNorm: abiraterone acetate

Sponsors & collaborators

AstraZenecalead sponsor

Merck Sharp & Dohme LLCcollaborator

Mapped research locations

BeijingChina5 ShanghaiChina2 GuangzhouChina2 NanjingChina1 ChongqingChina1 Xi'anChina1 NanchangChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05171816 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.